Press Releases

Nanotherapeutics Announces Election of New Directors and Officers

Business Wire - January 2008

Weaver H. Gaines, Director and Chairman of the Board
James R. Butler, Robert J. Hennessey, and James M. Matthew, Directors
Dennis S. Kristof, Treasurer
Bärbel Eppler, Ph.D., Secretary
James F. Kirk, Ph.D., Vice President R&D

Nanotherapeutics' Board of Directors elected Weaver H. Gaines as the company’s new non-Executive Chairman. Mr. Gaines is a serial entrepreneur, with 35 years of executive, legal, and entrepreneurial experience, particularly in early stage companies. He is also a trustee of Torrey Pines Institute of Molecular Studies and a director of the Florida Research Consortium. In other actions, the Board increased the number... more >

Nanotherapeutics Awarded $20 Million NIAID/BARDA Contract to Develop Inhaled Gentamicin for Treatment of Aerosol Exposure to Bioterrorism Agents

Business Wire - October 2007

Nanotherapeutics has been awarded a $20 Million 4-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA) to develop an inhaled version of the injectable drug, gentamicin, a broad-spectrum antibiotic that is used as a first-line therapy for pneumonic plague and tularemia, Category A bioterrorism agents. Both diseases are highly infectious and could pose a serious danger if used as an aerosolized biological weapon. Using its novel particle formulation, the company has developed NanoGENT™, an inhaled dry-powder formulation of gentamicin, to provide early treatment for exposure to biological warfare agents, as well as TB and other respiratory infections.more >

HHS Awards Contracts for Advanced Development of New Medical Countermeasures

Department of Health and Human Services (HHS) - October 2007

The Department of Health and Human Services (HHS) announced today the award of contracts totaling $55.3 million to four companies for the advanced development of anthrax antitoxins, therapeutics and antibiotics for use against plague and tularemia. The new Biological Advanced Research and Development Authority (BARDA) and NIH s National Institute for Allergy and Infectious Diseases (NIAID), provided funding for the new contracts. Through an agreement with BARDA, NIAID will manage the contracts.more >

Nanotherapeutics and the Vaccine Branch of the National Cancer Institute enter into Cooperative Research and Development Agreement (CRADA)

Yahoo Finance! / www.nanotherapeutics.com - August 2007

Nanotherapeutics, Inc. has entered into a two year Cooperative Research and Development Agreement (CRADA) with the Vaccine Branch of the National Cancer Institute (NCI) to produce HIV peptide oral vaccine nanoparticles using the company's proprietary technology. The collaboration with NCI will employ the company's nanoparticle delivery system, which enables oral targeted delivery of macromolecules such as peptides, to facilitate oral delivery in the GI tract to improve immune response.more >

Nanotherapeutics, Inc. Named Most Promising Nanotechnology Industry Startup

www.asme.org (American Society of Mechanical Engineers) - October 2006

Nanotherapeutics, Inc., a specialty pharmaceutical company based in Alachua, Fla., was cited as the most promising nanotechnology industry startup company in a recent competition conducted by ASME. Nanotherapeutics was one of six finalists in the 2006 NanoVenture Competition, held Sept. 21 in Honolulu. The competition ran in conjunction with the ASME Multifunctional Nano-composites International Conference.more >

RFM To Participate in Nanotherapeutics' Potential $2.4 Million SBIR Contract for Improvised Explosive Device Detection

Yahoo! Finance - February 2006

RF Monolithics, Inc. today announced that its Wireless Systems Group is participating in a Small Business Innovation Research (SBIR) contract awarded to Nanotherapeutics, Inc. to develop an improved system to detect improvised explosive devices (IEDs).more >

Nanotherapeutics, Inc. Appoints Mento A. "Chuck" Soponis Chairman and CEO

www.businesswire.com - January 2006

Nanotherapeutics, Inc., a privately held corporation focused on the development and application of proprietary drug delivery systems, announced today the appointment of Mento A. "Chuck" Soponis as Chairman and CEO to lead the company into its next phase of growth. Company also announces: New U.S. Patent Issued, $5.6 Million in Funding from the U.S. Navy and...more >

NIAID Awards $47 Million in New Effort to Develop Medical Countermeasures Against Radiological and Nuclear Threats

National Institute of Health News - October 2005

The National Institute of Allergy and Infectious Diseases (NIAID) has issued more than $47 million for grants, contracts and interagency agreements as part of a new National Institutes of Health (NIH) research program on Medical Countermeasures Against Radiological and Nuclear Threats.more >

NIAID Awards First $27 Million Using New Bioshield Authorities

National Institute of Health News - May 2005

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new...more >